|Mr. Derek J. Maetzold||Founder, CEO, President & Director||1.45M||203.3k||1962|
|Mr. Frank Stokes||CFO & Treasurer||849.36k||62.36k||1970|
|Ms. Kristen M. Oelschlager R.N.||Chief Operating Officer||782.7k||136.74k||1968|
|Mr. Tobin W. Juvenal||Chief Commercial Officer||782.7k||68.94k||1960|
|Camilla Zuckero||Vice President of Investor Relations & Corporate Affairs||N/A||N/A||N/A|
|Ms. Alice Bahner Izzo||Senior Vice President of Marketing||N/A||N/A||N/A|
|Ms. Keli Greenberg||VP of Human Resources & Executive Director of Human Resources||N/A||N/A||N/A|
|Dr. Robert W. Cook Ph.D.||Senior Vice President of Research & Development||N/A||N/A||1972|
|Mr. Bernhard E. Spiess||Company Secretary||528.35k||N/A||1960|
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary 35-GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.
Castle Biosciences, Inc.’s ISS governance QualityScore as of 1 December 2023 is 9. The pillar scores are Audit: 4; Board: 5; Shareholder rights: 8; Compensation: 10.